HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies ABC- type AI alcohol consumption ALK alzheimer's Angiogenesis antibody drug conjugates Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 BCL6 benign Biofluid biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers biomarkers Bladder Bladder Cancer Bladder cancer blindness Breast Cancer Breast milk Burkitt lymphoma Cancer Genomics CAR-T-cells Castleman Disease CD10 CD8 CDKN1A Cells Cerebrospinal Fluid Cetuximab Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating tumor cells cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA Cytokine Cytokines Cytotoxic T Cells dementia Dementia Diabetes Differential Expression Differential Gene Expression Analysis diffuse large B-cell lymphoma DLBCL DLBCL COO Drug Response Drug Safety Drug Targets Drug-induced Liver Injury ear EGFR Muatations EMT Endothelial cell epidemiology epidermal growth factor receptor EGFRHER epigenomics Epstein-Barr Esophageal Cancer Exosomes Extracellular Vesicles extraction-free RNA workflow Fabry Disease Feasibility FFPE FGF Ligand Trap Fibrous Tumors FOLFOX7 Gene Expression Profiling Gene Signature Analysis Glioblastoma Tumors HCC Head and Neck Cancer Head and neck cancer Heart hepatocellular carcinoma HLA-E HPV HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune Tolerance Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours immunotherapy Immunotherapy Inflammation IRF4 JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Limb ischemia limbal stem cell deficiency LSCD Liquid Biopsy Liver liver disease Lung Lung cancer Lymph Node Metastasis lymphatic Lymphoid Neoplasia Lymphoma machine learning Machine Learning malignant Mechanism of Action Melanoma Mesothelioma metastatic colorectal cancer CRC Microenvironment microRNA MicroRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mTOR pathway multi-omics MUM1 Muscle Mutations NAFLD Nash and Fibrosis Neoantigens Neuroendocrine Tumor Neurologic NKG2A Non-alcoholic fatty liver disease Non-small cell lung cancer nuclease protection assay obesity OBP Oncology Oncology-Biomarker OPSCC Oral Cancer Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoclast Ovarian cancer Pan-Cancer Pancreas Pancreatic Cancer Paralysis Pathogenesis pathophysiology Pathway Analysis Pathway analysis PBMCs PCA Cell Lines PD-1 PD-L1 PIP placenta Placenta Plasma Plasma miRNAs PMAIP1 population based Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Progression free-survival Prostate Prostate Cancer qNPA Refractory DLBCL Relapsed DLBCL Reproductive Response rate Reveal Rheumatoid Arthritis Risk Score sarcoma Sarcoma Sequencing Serum Signaling Inhibitors Signatures single cell Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Synovial Fluid Synovial Sarcoma synthetic miRNA T-Cell T-cells targeted therapeutics Technology Comparison Therapeutic targets Thyroid Cancer tislelizumab TMB tomentosin Toxicity Transcriptome transcriptome profiling Translational Medicine Treatment Outcome Tumor Biology Tumor Heterogeneity Tumor Microenvironment Urothelial carcinoma Uterus vestibular schwannoma VS Wound healing Xenograft Tissue

2020

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma

Lenz, G., et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma. Leukemia 2020 (34) 2184-2197. https://doi.org/10.1038/s41375-020-0743-y

Download pdf 848KB

2019

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, A., et al. Journal of Clinical Oncology 2019 Mar22;37(15):1285-1295. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Download pdf 1.2MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

2017

Page last updated October 27, 2022